In collaboration with AstraZeneca, we launched a PDX consortium to develop a collaborative, pre-competitive PDX resource.
The resource will streamline discovery and access to molecular data from PDX models to suit specific needs in oncology research. Use the following links to find out more:
For any further information, please email firstname.lastname@example.org
Tumour cells from a cancer patient are transplanted into mice that do not reject human cells.
The transplant in the mouse continues to grow within the tumour microenvironment.
Each PDX model comes from a single patient and - like every cancer - has a unique genetic make-up.
Researchers across many labs, including the PDX providers, are using a variety of techniques to map the genomic characteristics of each model, including genotyping, gene expression and whole-genome sequencing.
The Repositive PDX resource is a catalogue of PDX models from a range of PDX providers, allowing researchers to directly find and compare PDX models based on their characteristics and genetic makeup.
By maximising availability and reuse of existing PDX data, the oncology research units will shorten their time for data access and speed up their PDX experiments.
Benefits for PDX Users
Accelerate your research
Find and compare the PDX models that suit your needs quickly & efficiently.
Streamline your search process
Access many vendors through a unified search engine with PDX-tailored functionality.
Get standardised data
Our standardised data view will allow for easy search, evaluation and comparison.
Benefits for PDX Vendors
Generate new leads & showcase your expertise
Enable customers to find you by showcasing your listings & specialised expertise.
Gather broad market analytics
Understand the marketplace & consumer needs using statistics & analytic tools.
Streamline your workflow
Our user-friendly platform will help you manage your PDX model inventory.